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Abstract Recent developments in intrabronchial administration of insulin raise lung function in patients with type1
diabetes as important issue. Several studies in adults report abnormalities of lung function of these patients.The aim of
this studywas to investigate lung function in childrenwithtype1diabetes.
Twenty-seven children with type 1 diabetes performed measurement of airway obstruction (forced flow-volume
curves), lung volumes and airwayresistance (bodyplethysmography) and of pulmonarycarbonmonoxide diffusion capa-
city.
Mean age (7SD) of the childrenwas12.875 years.Mean time between the detection of type1diabetes and the lung
function testswas 5.5 yearswith a variation from1to17 years.The total airwayresistance (Raw) was significantlyhigher
compared to the reference values (Po0.001).The other lung function parameters were not significantly different from
reference values (P40.05).In this relatively small studyno relationship betweenlung function abnormalities and age, the
duration of disease or level of HbA1c was observed.
Ourdata show thatincreaseof airwayresistancedo occurinchildrenwithtype1diabetes.Progressive abnormalitiesin
lung function might interfere with the promising results of treatment with intrabronchial administration of insulin.
r 2002 Elsevier Science Ltd.Allrights reserved.
Available online athttp://www.sciencedirect.com
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Inhaled insulin therapy in diabetics has been tried for
more than 25 years, butbecame only recently successful
in clinical trials of patientswith type1diabetes (1). Subse-
quent correspondence on this topic made it clear that
the safety of inhaled insulin with regard to cardiac and
lung function should be considered (2). Lung function is
extremely important for optimal drug deposition as ex-
empli¢edbypatientswith asthma or chronic obstructive
lung disease (COPD). Therefore, the study of lung func-
tion in type1diabetes deserves new attention.
Several studies in adults with type 1 diabetes report
abnormalities in lung function of thesepatients. Reduced
lung volumes (3,4), and a reducedcarbonmonoxide di¡u-
sion capacity have been described (3^5).Received 26 February 2002, accepted in revised form 8 June 2002
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into lung function abnormalities in children with type 1
diabetes. Two studies showed signi¢cant reduction of
lung volumes (forced vital capacity, FVC) in diabetic
children compared to reference values (6,7). One study
showed signi¢cant increase of airway resistance (Raw)
and normal lung volumes in childrenwith type1diabetes
(8). Carbon monoxide di¡usion capacity (DLCO) was
not studied in children until now.Because of the scarcity
of data in children with type 1 diabetes and the
importance of lung function for proper pulmonary
drug delivery, we studied the lung function more
extensively.
PATIENTSANDMETHODS
Twenty-seven patients with type 1 diabetes were re-
cruited from the endocrinology outpatient department
of the Wilhelmina Children’s Hospital. None of the
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smokers.None of themused inhaled insulin.
All patients performed maximal expiratory £ow vo-
lume curves, with use of a pneumotachometer system
with a Lilly head (MasterScreen Pneumo, Erich Jaeger,
Wˇrzburg,Germany).These curves provide data on air-
way obstruction (forced expiratory volume in 1/s, FEV1)
and on lung volume (FVC).Total lung capacity (TLC), re-
sidual volume (RV) and Raw were measured in a body-
plethysmograph (Masterlab, Erich Jaeger, Wˇrzburg,
Germany). For reference values data of Zapletal were
used (9).Carbon monoxide di¡usion capacity, corrected
for alveolar volume (DLCO/VA)wasmeasuredusing a stan-
dardised singlebreath technique (Masterlab,Erich Jaeger,
Wˇrzburg,Germany). Reference values for DLCO/VA for
healthy Dutch children were used (10). All lung function
measurements were performed according to the ATS/
ERS standards.
Results are presented asmeanvalues of percentage of
predicted7SD. For comparison with normal values one
sample t-tests were used. To study correlation between
lung function and age, duration of disease and HbA1c a
Spearman rank correlation test was used. The study
was approvedby the hospitalmedical ethics committee.
RESULTS
Mean age of the childrenwas12.875.0 years.Mean time
between the detection of type 1 diabetes and the lung
function tests was 5.5 years with a variation from1to17
years. Mean HbA1c was 8.5% with a variation from 6 to
16.9%.
Mean FEV1was109712% of the predicted values, FVC
103712%, TLC 100712%, RV 105736%, DLCO/VA
119720%.These lung function parameters were not sig-
ni¢cantly di¡erent from reference values (P40.05), and
all valueswerewithin the 95% con¢dence intervals.Mean
Raw136749%, whichwas signi¢cantly higher compared
to the reference values (Po0.001). Raw values in nine
childrenwere above the 95% con¢dence interval.
We found no statistically signi¢cant correlation be-
tween lung function values and age, disease duration or
HbA1c.
DISCUSSION
In our group of children with type1diabetes we found a
statistical signi¢cant increase of total airway resistance
(Raw), while lung volumes, FEV1 and carbon monoxide
di¡usion capacity were normal. In this relatively small
study we could not ¢nd a correlation between lung func-
tion values and age, disease duration or HbA1c.However,
this study shows that even in children with a relatively
short history of type 1 diabetes, pulmonary abnormal-
itiesmay exist.The most important ¢nding of our study was an in-
crease of airwayresistance, which is in linewith the ¢nd-
ings in another group of children with type 1 diabetes,
described by Verrotti et al. (8). Although several studies
on lung function in adults with type 1 diabetes are de-
scribed, only few authors measured airway resistance.
In one small study with 11 patients between 21 and 28
years of age Raw was increased compared to normal
controls, but the di¡erence did not reach statistical sig-
ni¢cance (11).
The explanation for increase of airway resistance is
unclear. In adults with type1diabetes increased glycosy-
lation of tissue proteins has been described, which can
result in increased cross-linkage of collagen and elastin
(12). Increased cross-linkage of tissue proteins in the
lungs might explain the sti¡er behaviour of the airways
and the increase of airway resistance. In adult patients
with type 1 diabetes thickening of the basal membrane
has been described (13), which also might result in in-
creased airway resistance. Whether this phenomenon
also plays a role in children in unknown. Recent studies
have shown the success of administration of insulin in
the bronchial tree (1,2). In general, the e⁄cacy of drug
delivery by aerosol largely depends on the inspiratory
£ow rate that can be achieved by a patient. Increase of
airway resistance can decrease inspiratory £ow rates.
This argues for further studies into the airway resistance
in children and adultswith type1diabetes, because bron-
chial pathology and increase of airway resistance might
interfere with proper deposition and absorption of in-
trabronchial insulin.
Several studies in adult patients with type 1 diabetes
show a decrease of lung volumes (FVC and TLC, 3,4).
The prevalence of restrictive lung disease in adults sug-
gests that this phenomenonmightberelated to thedura-
tion of diabetes.Whether theserestrictive abnormalities
result from pulmonary or extrapulmonary pathology
and whether these abnormalities are preceded by in-
creased airway resistance is unknown. Decrease of re-
spiratory muscle function has been suggested (14), but
longitudinal data are lacking.
In our study values of FVC and FEV1were in the nor-
mal range, which is in linewith data in children described
by Verrotti et al. (8) Two other studies in children de-
scribed decreased vital capacity and normal values of
FEV1 (6,7). Maybe recent treatment regimens are more
e¡ective in preventing early lung damage.
Several studies in adults with type 1 diabetes have
shown decreased di¡usion capacity of carbon monoxide
(5),while data in children are lacking.Decreaseddi¡usion
capacity points to interstitial lung pathology with
thickening of the alveolo-capillary membrane. We did
not ¢nd di¡usion disturbances in our young patients. It
has been suggested that di¡usion abnormalities are due
to the development of pulmonary microangiopathy (12).
Progressive pulmonary microangiopathy may cause
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tientswith advanced type1diabetes.This is an important
¢nding, because it has been shown that intensive therapy
e¡ectivelydelays the onsetofmicroangiopathy and slows
the progression of diabetic retinopathy, nephropathy
and neuropathy.
When studying lung function in children it is important
to compare the results with adequate reference values.
Whilereference data inDutch children are lacking,usually
the reference data of Zapletal are used (9,15). Although
themean spirometric results were above100% predicted,
all patients had results within the 95% con¢dence inter-
vals. One-third of patients had Raw values above the
95% con¢dence interval, which suggests a real increase
of Raw in a signi¢cant proportion of our children (15).
Our data show that increase of airway resistance do
occur in children with type1diabetes. Data in literature
suggest increase of lung function abnormalities during later
life, especiallydecrease of lungvolumes andcarbonmonox-
ide di¡usion capacity. A long-term follow-up study in larger
groups ofpatients isneeded to describe therelationshipbe-
tween lung function abnormalities and the duration and se-
verity of the disease. Progressive abnormalities in lung
function might interfere with the promising results of
treatment with intrabronchial administration of insulin.
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